封面
市場調查報告書
商品編碼
2136464

2016-2026年皮膚病學領域的合作與授權協議

Dermatology Collaboration and Licensing Deals 2016-2026

出版日期: | 出版商: Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

讓我們透過 506 個真實世界的合作與授權協議案例來了解皮膚病學領域合作的趨勢。

《2016-2026 年皮膚病學領域的合作與許可協議》提供了有關皮膚病學領域資產、技術和開發計劃的 506 項合作交易的全面資訊。

我們在皮膚病學領域的合作涵蓋了廣泛的治療適應症、技術和發展策略,從創新療法和生物製藥到應對發炎性疾病、免疫介導性疾病和其他皮膚疾病的廣泛方法。

本報告將這些趨勢匯總在一個資源中,使用戶能夠了解哪些公司正在建立合作關係,哪些皮膚病學機會正在吸引關注,交易結構是什麼,披露了哪些財務條款,以及交易如何根據適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單;它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為皮膚病學領域的業務發展、許可、交易來源和評估、公司策略、研發策略、競爭情報以及參與合作的法律團隊提供可操作的資訊和基準資源。

了解皮膚科領域的合作趨勢

本報告分析了2016年至2026年皮膚病學領域的交易情況,內容包括:

  • 皮膚病學領域合作的年度趨勢
  • 按交易類型分類的交易趨勢
  • 產業部門
  • 合作關係發展階段
  • 技術類型
  • 皮膚科適應症
  • 皮膚科領域最活躍的交易商
  • 根據已揭露的交易金額,主要交易金額
  • 皮膚病學領域合作活動的趨勢
  • 這使用戶能夠確定他們的活動集中在哪些方面,並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
  • 對皮膚病學領域合作關係的財務條款進行基準分析
  • 財務條款可能因所涉資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析,包括以下內容:

  • 交易總額
  • 預付款
  • 里程碑付款
  • 版稅率
  • 透過分析這些基準背後的具體交易,用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
  • 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
  • 財務基準只有在結合類似交易的結構和情況進行解讀時,才能發揮其最大效用,而不僅僅將其視為平均值。本報告提供了建構這種背景所需的交易基本資訊。
  • 確定皮膚病學領域的關鍵交易商和潛在合作夥伴。
  • 本報告列出了在皮膚病學領域合作活動最活躍的公司,並提供交易歷史記錄,以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容:

  • 積極尋求皮膚病學領域商機的公司
  • 潛在的許可和合作研究夥伴
  • 我們與一些組織就特定皮膚病學適應症進行過多次合作。
  • 積極參與開發過程的公司
  • 對特定技術或方法表現出興趣的交易商
  • 競爭對手採取類似的外部創新策略
  • 對於在皮膚病學領域尋求資產和技術合作夥伴的公司而言,過去的交易歷史可以提供寶貴的見解,了解哪些組織對類似的機會表現出了興趣。
  • 依皮膚科適應症比較合作活動。
  • 皮膚科領域涵蓋多種不同的治療適應症,每種適應症都有其獨特的臨床、競爭和商業性趨勢。
  • 本報告按皮膚病治療適應症分析交易,使用戶能夠專注於與特定項目或策略關注事項最相關的交易,而不是依賴廣泛的市場層級基準。
  • 透過結合基於技術和發展階段的分析,用戶可以發現更多有意義的類似交易和潛在的未來合作夥伴關係。
  • 了解皮膚病學領域的合約結構
  • 本報告涵蓋合作、授權、開發、研發及其他合作交易。

根據交易詳情和資訊披露,用戶可以調查以下方面:

  • 授予和保留的權利
  • 研發職責
  • 授權權
  • 獨家版權
  • 區域權利
  • 智慧財產
  • 發展和監管義務
  • 製造和供應方面的職責
  • 商業化權利
  • 金錢補償
  • 里程碑和版稅
  • 管治
  • 合約期限和終止條款
  • 這些例子對於考慮皮膚病學領域合作的適當框架將很有用。
  • 從實際合約中學習
  • 本報告提供了公開可取得的與選定的皮膚病學相關交易的基礎合約文件的途徑。

這些合約提供的資訊遠比簡單的標題公告詳細得多,使用戶能夠檢驗公司如何記錄以下內容:

  • 權利範圍
  • 發展義務
  • 智慧財產
  • 獨家版權
  • 財務狀況
  • 里程碑觸發條件
  • 特許權使用費規定
  • 商業化權利
  • 合約終止及其他待討論事項
  • 對於準備和談判皮膚病學領域合作與許可協議的團隊來說,獲取實際的合約措辭可以讓他們深入了解類似交易的實際結構。
  • 綜合皮膚病學交易目錄
  • 本報告包含皮膚病學領域 506 項合作與許可協議的綜合目錄,提供詳細資訊來源,以便識別相關的領先交易。

在以下條件下可以查看交易記錄:

  • 公司
  • 技術類型
  • 治療指徵
  • 合約揭露狀態
  • 每筆交易都與其底層交易記錄相關聯,從而可以存取詳細的交易資訊和相關的合約文件(如有)。
  • 誰該使用這份報告?
  • 業務拓展與授權團隊
  • 識別皮膚病學領域中的類似交易、潛在合作夥伴和相關交易結構。
  • 研究與評估團隊
  • 這樣一來,您就可以找到那些正在積極探索皮膚病學領域特定適應症、技術和發展階段的商業機會的公司。
  • 尋求合作夥伴的生技公司
  • 找出對類似皮膚病學相關資產、技術和開發項目表現出明確興趣的組織。
  • 企業策略與研發策略團隊
  • 我們將了解我們的競爭對手和潛在合作夥伴如何透過外部創新來建立其皮膚病產品組合。
  • 競爭情報與市場情報團隊
  • 我們按公司、適應症、開發階段和技術追蹤合作趨勢,以了解不斷變化的策略重點。
  • 法律及交易團隊
  • 我們將仔細審查公開的合約和以往的合約結構,以幫助您準備和談判交易。
  • 我們將來自整個市場的皮膚病學相關資訊轉化為公司專屬的洞察。
  • 對於符合資格的客戶,Current Partnering 不僅會提供報告,還會為高階主管提供客製化的合作關係簡報。
  • 本次簡報將說明有關皮膚病交易的基礎信息,並根據您的特定資產、技術、適應症或合作目標量身定做。
  • 如有需要,我們可以提供相關的類似交易、潛在合作夥伴、競爭對手活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
  • 請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章:引言

第2章:皮膚病學領域交易趨勢

  • 迄今為止皮膚病學領域合作的趨勢
  • 皮膚病學領域按交易類型分類的合作關係
  • 皮膚病學領域合作的行業特定趨勢
  • 皮膚科領域不同發展階段的合作
  • 按技術類型分類的皮膚病學領域合作
  • 基於治療適應症的皮膚科領域合作

第3章 皮膚病學領域合夥企業的財務條件

  • 已披露皮膚病學領域合作的財務條款
  • 皮膚病學領域合作計畫的主要合約金額
  • 皮膚科交易中的預付款
  • 皮膚病交易中的里程碑付款
  • 皮膚病學領域的版稅率

第4章 皮膚病學領域的代表性交易及主要交易負責人

  • 在皮膚病學領域合作最活躍的公司
  • 皮膚病學領域最活躍的交易商名單
  • 皮膚科領域主要交易金額:以價值計算

第5章:皮膚病學領域合約文件目錄

  • 皮膚病學領域內有合約文件的合作專案。

第6章:基於治療標靶的皮膚病學領域交易

  • 皮膚病治療目標交易
  • 交易目錄
  • 交易目錄 - 按公司名稱(A-Z)列出的皮膚病學領域交易
  • 交易目錄 - 按技術類型分類的皮膚科交易
  • 交易類型的定義
  • 關於生物製藥研究
  • Current Partnering
  • Current Agreements
  • 理想合作夥伴近期報告標題
簡介目錄
Product Code: CP2216

Understand the dermatology partnering landscape using intelligence from 506 real-world collaboration and licensing deals.

Dermatology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 506 partnering deals involving dermatology assets, technologies and development programs.

Dermatology partnering encompasses a diverse range of therapeutic indications, technologies and development strategies, from innovative therapeutics and biologics through to broader approaches addressing inflammatory, immune-mediated and other dermatological conditions.

The report brings this activity together in one resource, enabling users to understand who is partnering, which dermatology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in dermatology partnering.

Understand the dermatology partnering landscape

The report analyzes dermatology dealmaking from 2016 to 2026, including:

  • Trends in dermatology partnering by year
  • Deal activity by deal type
  • Industry sector
  • Stage of development at the time of partnering
  • Technology type
  • Dermatology therapeutic indication
  • Most active dermatology dealmakers
  • Leading deals by disclosed value
  • How dermatology partnering activity is evolving
  • This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
  • Benchmark dermatology deal financials
  • Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

  • Headline deal values
  • Upfront payments
  • Milestone payments
  • Royalty rates
  • Users can then investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
  • This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
  • Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
  • Identify leading dermatology dealmakers and prospective partners
  • The report identifies the most active companies in dermatology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

  • Companies actively seeking dermatology opportunities
  • Prospective licensing and collaboration partners
  • Organizations repeatedly partnering in particular dermatology indications
  • Companies active at relevant stages of development
  • Dealmakers demonstrating interest in specific technologies or approaches
  • Competitors pursuing similar external innovation strategies
  • For companies seeking to partner a dermatology asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
  • Compare partnering activity across dermatology indications
  • Dermatology encompasses multiple distinct therapeutic indications with different clinical, competitive and commercial dynamics.
  • The report analyzes deals by dermatology therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
  • Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable transactions and prospective partners.
  • Understand how dermatology agreements are structured
  • The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

  • Rights granted and retained
  • Research and development responsibilities
  • Licensing rights
  • Exclusivity
  • Geographic rights
  • Intellectual property
  • Development and regulatory obligations
  • Manufacturing and supply responsibilities
  • Commercialization rights
  • Financial consideration
  • Milestones and royalties
  • Governance
  • Term and termination provisions
  • These real-world examples provide useful reference points when considering the appropriate structure for a dermatology partnership.
  • Learn from real-world contract documents
  • Where publicly available, the report provides access to underlying contract documents for selected dermatology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

  • Scope of rights
  • Development obligations
  • Intellectual property
  • Exclusivity
  • Financial terms
  • Milestone triggers
  • Royalty provisions
  • Commercialization rights
  • Termination and other negotiated provisions
  • For teams preparing or negotiating a dermatology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
  • Comprehensive dermatology deal directory
  • The report includes a comprehensive directory of 506 dermatology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

  • Company
  • Technology type
  • Therapeutic indication
  • Contract availability
  • Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
  • Who should use this report?
  • Business Development and Licensing teams
  • Identify comparable dermatology transactions, prospective partners and relevant deal structures.
  • Search and Evaluation teams
  • Understand which companies are actively seeking dermatology opportunities across particular indications, technologies and development stages.
  • Biotechnology Companies Seeking Partners
  • Identify organizations with demonstrated interest in comparable dermatology assets, technologies and development programs.
  • Corporate and R&D Strategy teams
  • Understand how competitors and prospective partners are building dermatology portfolios through external innovation.
  • Competitive and Market Intelligence teams
  • Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
  • Legal and Transaction teams
  • Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
  • Turn market-wide dermatology intelligence into company-specific insight
  • For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
  • The briefing applies the underlying dermatology deal intelligence to the customer's own asset, technology, indication or partnering objectives.
  • Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
  • Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in dermatology dealmaking

  • 2.1. Introduction
  • 2.2. Dermatology partnering over the years
  • 2.3. Dermatology partnering by deal type
  • 2.4. Dermatology partnering by industry sector
  • 2.5. Dermatology partnering by stage of development
  • 2.6. Dermatology partnering by technology type
  • 2.7. Dermatology partnering by therapeutic indication

Chapter 3 - Financial deal terms for dermatology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for dermatology partnering
  • 3.3. Dermatology partnering headline values
  • 3.4. Dermatology deal upfront payments
  • 3.5. Dermatology deal milestone payments
  • 3.6. Dermatology royalty rates

Chapter 4 - Leading dermatology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in dermatology partnering
  • 4.3. List of most active dealmakers in dermatology
  • 4.4. Top dermatology deals by value

Chapter 5 - Dermatology contract document directory

  • 5.1. Introduction
  • 5.2. Dermatology partnering deals where contract document available

Chapter 6 - Dermatology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by dermatology therapeutic target
  • Deal directory
  • Deal directory - Dermatology deals by company A-Z
  • Deal directory - Dermatology deals by technology type
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Dermatology partnering since 2016
  • Figure 2: Dermatology partnering by deal type since 2016
  • Figure 3: Dermatology partnering by industry sector since 2016
  • Figure 4: Dermatology partnering by stage of development since 2016
  • Figure 5: Dermatology partnering by technology type since 2016
  • Figure 6: Dermatology partnering by indication since 2016
  • Figure 7: Dermatology deals with a headline value
  • Figure 8: Dermatology deals with upfront payment values
  • Figure 9: Dermatology deals with milestone payment
  • Figure 10: Dermatology deals with royalty rates
  • Figure 11: Active dermatology dealmaking activity since 2016
  • Figure 12: Top dermatology deals by value since 2016